This HTML5 document contains 27 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1495
rdf:type
owl:Class
rdfs:label
Intoplicine
rdfs:subClassOf
nci:C1748 nci:C582
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance Organic Chemical
nci:P108
Intoplicine
nci:P171
12570767
nci:P175
645008
nci:P207
C0217476
nci:P210
125974-72-3
nci:P319
FB2CIN6HMI
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A substance that has been studied in the treatment of some types of cancer. Intoplicine blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
43318
nci:P330
43318
nci:P350
C21H24N4O
nci:P366
Intoplicine
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>INTOPLICINE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>FB2CIN6HMI</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Intoplicine</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Intoplicine</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0645008</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>7H-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>intoplicine</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000046164</n0:source-code></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1495
n5:hasConcept
n6:M0218207